Eton Pharmaceutcials, Inc. Common Stock

Day range

$49.54 – $51.33

Open

$50.00

Prev close

$50.00

Volume

240.25K

Market cap

$1.43B

Shares out

28.58M

P/E

112.64

P/S

13.53

P/B

30.68

P/FCF

97.01

ROE

27.2%

ROA

11.0%

Debt/Equity

0.60

Div yield

0.00%

As of Oct 23, 2026

• Supply or distribution agreementOct 14, 2026

  In connection with the License Agreement, the Company also entered into a supply agreement with Aquestive under which Aquestive will serve as the exclusive manufacturer and supplier of the Product, subject to specified exceptions. The Supply Agreement provides for an initial term of 20 years.

• Product or service launchSep 28, 2026

  On September 28, 2026, Eton Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it has launched IMPAVIDO® (miltefosine) capsules.

• Licensing agreementAug 5, 2026

  On July 31, 2026, Eton Pharmaceuticals, Inc. entered into a license agreement (the "Agreement") for a late-stage rare disease product candidate ASN-001 (timolol topical gel) from Auson Pharmaceuticals Inc. for the treatment of proliferating superficial infantile hemangiomas.

• Executive officer appointmentAug 4, 2026

  On July 31, 2026, Eton Pharmaceuticals, Inc. (the "Company") appointed Danka Radosavljevic (age 42) as Chief Operating Officer. Ms. Radosavljevic previously held the position of Executive Vice President, Operations at the Company overseeing quality, product development, regulatory, supply chain and information systems for more than the past five years. Ms. Radosavljevic has been with the Company since 2017.

• Annual meeting resultsJun 9, 2026

  The 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Eton Pharmaceuticals, Inc. (the "Company") was held virtually on June 9, 2026. At the meeting, the Company's stockholders (1) elected the director nominees Jenn Adams and Charles J. Casamento for a three-year term and (2) ratified the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.

Days to cover

2.9

Short interest

1.83M

Avg volume

624.71K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• ETON Stock Surges 108% in Six Months: Here's What You Need to Know
  positiveZacks Investment Research· Oct 7, 2026
• Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
  positiveGlobeNewswire Inc.· Aug 27, 2026
• Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
  positiveGlobeNewswire Inc.· Aug 5, 2026
• Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
  positiveGlobeNewswire Inc.· Aug 3, 2026
• Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
  positiveBenzinga· Mar 2, 2026